BR0313881A - Remédio - Google Patents

Remédio

Info

Publication number
BR0313881A
BR0313881A BR0313881-0A BR0313881A BR0313881A BR 0313881 A BR0313881 A BR 0313881A BR 0313881 A BR0313881 A BR 0313881A BR 0313881 A BR0313881 A BR 0313881A
Authority
BR
Brazil
Prior art keywords
macrophages
medicine
exterminated
remedy
pathogen
Prior art date
Application number
BR0313881-0A
Other languages
English (en)
Inventor
Hiroshi Terada
Kimiko Makino
Gen-Ichiro Soma
Original Assignee
Hiroshi Terada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hiroshi Terada filed Critical Hiroshi Terada
Publication of BR0313881A publication Critical patent/BR0313881A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"REMéDIO". é intencionado fomecer um remédio para as doenças causadas pelos macrófagos com disfunção ou mediadas pelos macrófagos. Isto é, um remédio que ative a capacidade fagocítica de macrófagos e assim seja eficientemente incorporado nos macrófagos devido à fagocitose vigorosa. Como um resultado, os macrófagos com disfunção são normalizados, os macrófagos infectados com um patógeno são exterminados ou um patógeno nos macrófagos infectados é exterminado.
BR0313881-0A 2002-08-27 2003-08-27 Remédio BR0313881A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002247871 2002-08-27
PCT/JP2003/010871 WO2004019982A1 (ja) 2002-08-27 2003-08-27 治療薬

Publications (1)

Publication Number Publication Date
BR0313881A true BR0313881A (pt) 2005-08-30

Family

ID=31972490

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0313881-0A BR0313881A (pt) 2002-08-27 2003-08-27 Remédio

Country Status (19)

Country Link
US (4) US20060105048A1 (pt)
EP (2) EP2343072A1 (pt)
JP (1) JP3947999B2 (pt)
KR (3) KR20110002876A (pt)
CN (4) CN1935156A (pt)
AU (1) AU2003261768B2 (pt)
BR (1) BR0313881A (pt)
CA (2) CA2706622C (pt)
DK (1) DK1547615T3 (pt)
EA (1) EA008107B1 (pt)
ES (1) ES2575534T3 (pt)
HK (1) HK1145463A1 (pt)
HU (1) HUE030275T2 (pt)
MX (1) MXPA05002209A (pt)
PL (3) PL397022A1 (pt)
SG (1) SG151103A1 (pt)
UA (1) UA84276C2 (pt)
WO (1) WO2004019982A1 (pt)
ZA (1) ZA200502452B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007284362A (ja) * 2006-04-13 2007-11-01 Tokyo Univ Of Science 薬物送達粒子及びその製造方法
EA016540B1 (ru) * 2008-12-30 2012-05-30 Ооо "Научно-Производственный Комплекс "Наносистема" Фармацевтическая композиция для лечения туберкулеза, способ ее получения и способ лечения туберкулеза
JPWO2011037086A1 (ja) * 2009-09-28 2013-02-21 源一郎 杣 植物育成剤、植物病害抵抗性誘導剤及び病害防除方法
EP2508190B1 (en) 2009-12-03 2021-06-02 Aureo Co., Ltd. Macrophage phagocytosis-activating composition and/or composition promoting cytokine production in macrophages
CA2923030A1 (en) * 2013-10-03 2015-04-09 Nitto Denko Corporation Injectable vaccine composition
ES2908553T3 (es) * 2015-12-08 2022-05-03 Inst Nat Sante Rech Med Métodos para expandir una población de macrófagos alveolares en un cultivo de larga duración
JP7047058B2 (ja) * 2017-07-27 2022-04-04 サムヤン ホールディングス コーポレイション 生分解性高分子微粒子の製造方法及びそれにより製造される生分解性高分子微粒子
KR200490892Y1 (ko) 2019-02-26 2020-01-17 주식회사 남현 체압 연동형 의자 등받이 경사 조절기구
KR102210240B1 (ko) 2020-01-15 2021-02-01 주식회사 남현 탄성력 조절이 가능한 의자 등받이 경사 조절기구

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1739064A (en) * 1922-12-29 1929-12-10 Ind Waste Products Corp Process for the manufacture of a sugar product
DE69126183D1 (de) * 1990-08-20 1997-06-26 Den Ichi Mizuno LPS-produzierende Bakterien, Lipopolysiccharide und LPS enthaltende Arzneimittel und tierärztliche Medikamente
US5759583A (en) * 1995-08-30 1998-06-02 Syntex (U.S.A.) Inc. Sustained release poly (lactic/glycolic) matrices
US6126919A (en) * 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US6248345B1 (en) * 1997-07-02 2001-06-19 Euro-Celtique, S.A. Prolonged anesthesia in joints and body spaces
JP4204085B2 (ja) * 1997-10-08 2009-01-07 オリジナル・イメージ株式会社 マクロファージ活性化剤
BR9915462A (pt) * 1998-11-18 2001-12-11 Univ Florida Processos para preparação de partìculas dedroga revestidas e as suas formulaçõesfarmacêuticas
JP4580479B2 (ja) * 1998-12-21 2010-11-10 株式会社林原生物化学研究所 抗ｈｉｖ感染症剤
US6406745B1 (en) * 1999-06-07 2002-06-18 Nanosphere, Inc. Methods for coating particles and particles produced thereby
JP2002247871A (ja) 2001-02-15 2002-08-30 Matsushita Electric Ind Co Ltd モータ制御装置及びモータ制御方法

Also Published As

Publication number Publication date
AU2003261768B2 (en) 2009-01-15
JPWO2004019982A1 (ja) 2005-12-15
US20140206641A1 (en) 2014-07-24
EP1547615B1 (en) 2016-04-13
US20060105048A1 (en) 2006-05-18
CN1935156A (zh) 2007-03-28
WO2004019982A1 (ja) 2004-03-11
HK1145463A1 (en) 2011-04-21
CN101862456A (zh) 2010-10-20
EP1547615A4 (en) 2007-05-02
EA200500418A1 (ru) 2005-10-27
CN1678350A (zh) 2005-10-05
AU2003261768A1 (en) 2004-03-19
PL397022A1 (pl) 2012-03-26
UA84276C2 (uk) 2008-10-10
CN101862456B (zh) 2012-11-28
KR20110002876A (ko) 2011-01-10
ES2575534T3 (es) 2016-06-29
ZA200502452B (en) 2006-08-30
EP2343072A1 (en) 2011-07-13
CN1935155A (zh) 2007-03-28
US20100178354A1 (en) 2010-07-15
KR20110002877A (ko) 2011-01-10
DK1547615T3 (en) 2016-06-06
MXPA05002209A (es) 2005-09-12
PL397023A1 (pl) 2012-03-26
US8425939B2 (en) 2013-04-23
CA2496902C (en) 2012-01-03
KR101067971B1 (ko) 2011-09-26
KR20050057064A (ko) 2005-06-16
CA2706622C (en) 2015-11-03
EP1547615A1 (en) 2005-06-29
US20130202663A1 (en) 2013-08-08
CA2496902A1 (en) 2004-03-11
EA008107B1 (ru) 2007-04-27
PL375585A1 (en) 2005-11-28
HUE030275T2 (en) 2017-05-29
SG151103A1 (en) 2009-04-30
CA2706622A1 (en) 2004-03-11
JP3947999B2 (ja) 2007-07-25

Similar Documents

Publication Publication Date Title
UY27186A1 (es) Formulación farmacéutica
BRPI0410684A (pt) uso de um peptìdio conjugado a uma proteìna que age como um imunógeno para a produção de anticorpos capazes de reconhecer especificamente qualquer uma das variantes predominantes do peptìdeo beta amilóide aß40 e aß42 na preparação de um medicamento para a prevenção e/ou o tratamento de uma doença e uso de um anticorpo ou um fragmento ativo ou o derivado de um anticorpo que reconhece especificamente qualquer uma das variantes predominantes do peptìdio beta amilóide, aß40 e aß42, na preparação de um medicamento para prevenção e/ou tratamento de uma doença
BRPI0704238A (pt) preventivo da doença de coccidiose e clostrìdica e/ou terapia para a doença de coccidiose e clostridica
AR037109A1 (es) Uso de flibanserina
BR0313881A (pt) Remédio
GT200300149A (es) Formulacion farmaceutica
ECSP066365A (es) Anilino purinas sustituidas en la posición 6 útiles como inhibidores de rtk
NI201000093A (es) Toalla para llevar puesta
CY1105849T1 (el) Χρηση αντισηπτικων στην εμπορικη κατασκευη φαρμακευτικου παρασκευασματος προς αποτροπη ή θepαπεια εναντι φλεγμονων εντος του ανθρωπινου σωματος
UY31403A1 (es) "derivados novedosos de ({((3-metilfenil)-2h-tetrazol-5-il)-etoxi} -4h-1,2,4-triazol-3-il), composiciones farmacéuticas conteniendolos y uso médico de los mismos".
BR0210013A (pt) Gel oftálmico de pirenzepina
PA8494501A1 (es) Sal mutua de amlodipino y atorvastatina
HN2003000183A (es) Difenilazetidinonas sustituidas en anillo procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
AR042550A1 (es) Una forma de dosificacion farmaceutica que comprende venlafaxina y memantina
BR0313769A (pt) Artigo descartável de vestir
CY1115194T1 (el) Χρηση της μακρας πεντραξινης ptx3 για την προληψη ή θεραπεια ιικων ασθενειων
AR036877A1 (es) Formulacion farmaceutica
TR200103249T2 (tr) Migrenin tedavisi ve önlenmesinde valproik asit analoğu kullanımı.
AR039843A1 (es) Tratamiento de padecimientos post-menopausicos en pacientes con cancer de mama
GT200400134A (es) Sistemas emulsionantes que contienen derivados de azetidina
WO2019023664A3 (en) VAGINAL THERAPY DEVICE BASED ON LIGHT
PA8624501A1 (es) Piperazinas derivadas de úrea para el tratamiento de la endometrosis
AR023452A1 (es) Utilizacion del osanetant para preparacion de medicamentos utiles en el tratamiento de los trastornos del humor
AR049220A1 (es) Uso de 7-ter-butoxiiminometilcamptotecina en la preparacion de un medicamento util para el tratamiento de neoplasmas uterinos
AR030522A1 (es) Tratamiento de quemaduras

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B07C Technical examination (opinion): republication [chapter 7.3 patent gazette]

Free format text: REFERENTE AO DESPACHO 7.5, PUBLICADO NA RPI 2411 DE 21/03/2017, PARA CORRECAO DE DOCUMENTOS.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]